Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2025; 31(47): 114377
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114377
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114377
Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens for Helicobacter pylori eradication in Sichuan Province, China
Chao-Qun Wu, Xiu Zhou, Chang-Ping Li, Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
Qing-Ling He, Zong-Hua Chen, Department of Gastroenterology, Yibin Second People’s Hos
Shun-Bin Ding, Lei Deng, Department of Gastroenterology, Deyang People’s Hospital, Deyang 618000, Sichuan Province, China
Lin-Lin Chen, Department of Gastroenterology, Suining Central Hospital, Suining 629001, Sichuan Province, China
Kai Jiang, The Fourth Department of the Digestive Disease Center, Suining Central Hospital, Suining 629099, Sichuan Province, China
Cheng-Kui Dong, Department of Gastroenterology, Second People’s Hospital of Liangshan Yi Autonomous Prefecture, Xichang 615000, Sichuan Province, China
Lian Hu, Department of Gastroenterology, Yibin First People’s Hospital, Yibin 644000, Sichuan Province, China
Guo-Bing Zhu, Department of Gastroenterology, Longchang City People’s Hospital, Neijiang 641000, Sichuan Province, China
Cheng-Gang Zhang, Department of Gastroenterology, Ningnan County People’s Hospital, Ningnan 615400, Sichuan Province, China
Yan Zhang, Department of Gastroenterology, Zigong Fouth People’s Hospital, Zigong 643000, Sichuan Province, China
Li-Li Wu, Department of Gastroenterology, Suining First People's Hospital, Suining 629000, Sichuan Province, China
Wei Li, Department of Gastroenterology, Wenjiang District People’s Hospital, Chengdu 611130, Sichuan Province, China
Yi-Hong Mao, Department of Gastroenterology, Hejiang County People’s Hospital, Luzhou 646200, Sichuan Province, China
Hua Zhang, Department of Gastroenterology, Chengdu City Fifth People’s Hospital, Chengdu 611130, Sichuan Province, China
Xia Ai, Department of Gastroenterology, Deyang City Second People’s Hospital, Deyang 618000, Sichuan Province, China
Yuan-Qing He, Department of Gastroenterology, Longquanyi District People’s Hospital, Chengdu 610100, Sichuan Province, China
Yan Ma, Department of Gastroenterology, Xindu District Traditional Chinese Medicine Hospital, Chengdu 610500, Sichuan Province, China
Shuang-Yan He, Department of Gastroenterology, Tianfu New Area People’s Hospital, Chengdu 610000, Sichuan Province, China
Co-first authors: Chao-Qun Wu and Xiu Zhou.
Author contributions: Wu CQ and Zhou X participated in study conception, literature review, and drafting of the initial manuscript; Li CP designed and supervised the overall study, coordinated data analysis, and finalized the manuscript; He QL and Chen ZH were responsible for patient enrollment, clinical management, and follow-up; Ding SB and Deng L performed data collection and validation; Chen LL and Jiang K contributed to methodology development and database construction; Dong CK and Hu L assisted in data curation and statistical verification; Zhu GB and Zhang CG helped with interpretation of results and manuscript revision; Zhang Y, Wu LL, and Li W supported patient monitoring and safety assessment; Mao YH, Zhang H, Ai X, He YQ, Ma Y, and He SY provided technical assistance and contributed to clinical coordination; Li CP is the corresponding author, responsible for overall supervision, project administration, and final approval of the submitted version. Wu CQ and Zhou X contributed equally to this work.
Supported by Project Fund of the Health Commission of Sichuan Province, No. 19PJ290.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Boards of Clinical Research Ethics Committee of Southwest Medical University Affiliated Hospital (Approval No. KY2022272).
Clinical trial registration statement: The trial was registered at the Chinese Clinical Trial Registry (www.chictr.org.cn), No. ChiCTR2200065282.
Informed consent statement: All participants provided written informed consent prior to enrollment in the study.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest related to this study.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: Deidentified individual participant data and study materials are available from the corresponding author upon reasonable request for academic purposes.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chang-Ping Li, Professor, Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. 506854209@qq.com
Received: September 18, 2025
Revised: October 11, 2025
Accepted: November 6, 2025
Published online: December 21, 2025
Processing time: 92 Days and 22.4 Hours
Revised: October 11, 2025
Accepted: November 6, 2025
Published online: December 21, 2025
Processing time: 92 Days and 22.4 Hours
Core Tip
Core Tip: This multi-center randomized non-inferiority trial compared three vonoprazan (VPZ) plus amoxicillin (AMO) dual-therapy regimens: AMO 0.5 g QID, 0.75 g QID, and 1.0 g TID. All regimens achieved high eradication with excellent compliance and low adverse-event rates. The low-dose, high-frequency option (0.5 g QID) provided efficacy comparable to higher doses with superior tolerability, supporting dose optimization of VPZ-AMO as a practical first-line strategy in high-prevalence regions.